Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance
Yazan Jabban(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Cecilia Arana Yi(Mayo Clinic Hospital), Rong He(Mayo Clinic), J. Foran(Jacksonville College), Maleeha Shah(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mehrdad Hefazi(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Kurt Bessonen(Mayo Clinic in Arizona), Aasiya Matin(Mayo Clinic), David S Viswanatha(Mayo Clinic), Dragan Jevremovic(Mayo Clinic), Antoine N. Saliba(Mayo Clinic in Arizona), William J Hogan(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 0
Related Papers
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
|Leukemia|2018|250
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
|Haematologica|2019|215